Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
M3 ( (JP:2413) ) just unveiled an announcement.
The company delivered strong nine-month FY2025 results, with revenue climbing 28.6% to ¥264.4 billion and profit attributable to owners rising 28% to ¥41.7 billion on broad-based growth across its medical marketing and digital solutions, lifting EPS to ¥61.42 and bolstering comprehensive income by 44.2%. Management maintained full-year guidance calling for ¥360 billion in revenue and ¥45 billion in profit attributable to owners, while keeping dividend plans under review to balance capital needs—signals that M3 expects sustained demand for its healthcare platform despite the absence of a declared payout schedule.
The most recent analyst rating on (JP:2413) stock is a Hold with a Yen2092.00 price target. To see the full list of analyst forecasts on M3 stock, see the JP:2413 Stock Forecast page.
More about M3
M3, Inc. operates a digital health information platform through the Tokyo Stock Exchange, providing online medical portals, physician support services, and data-driven solutions for pharmaceutical and healthcare stakeholders worldwide.
Average Trading Volume: 3,800,463
Technical Sentiment Signal: Sell
Current Market Cap: Yen1297.4B
For detailed information about 2413 stock, go to TipRanks’ Stock Analysis page.